# Vivalyx

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vivalyx

- Industry: Medical Devices & Equipment
- Headquarters: Aachen, Germany
- Website: www.vivalyx.com
- Total disclosed funding: $5.8M
- Latest round: Seed (Mar 26, 2024)
- Investors on record: 8

## About

Based in Aachen, Germany, and founded in 2022 by Dr. Andreas Schumacher, Dr. Benedict Doorschodt, Prof. Dr. René Tolba, PD Dr. Christian Bleilevens, Prof. Dr. Malte Brettel, and Marius Rosenberg, Vivalyx GmbH, a.k.a. Vivalyx operates as an organ vitality technology company that focuses on developing and manufacturing solutions for the preservation of organs for transplantation. In April 2024, Vivalyx GmbH raised EUR 5.4 million in seed funding co-led by TechVision Fonds and Brightlands Venture Partners, with participation from Arve Capital and GOOSE Capital.

Vivalyx is facilitating organ preservation with its patented Omnisol solution, designed to increase organ vitality and quantity for transplantation. Omnisol offers a blood-free alternative for all preservation methods, resulting in improved clinical outcomes.

The company plans to use its proceeds from April 2024 funding to finance the clinical study required for regulatory approval.

## Funding rounds

- Seed, Mar 26, 2024, $5.8M — Brightlands Venture Partners, GOOSE Capital, Angel Invest Ventures, TechVision Fonds, Arve Capital, Leblon Capital, Inari Ventures I GmbH & Co. KG, Wilde Ventures Gmbh

## Investors

- Brightlands Venture Partners (https://capitalatlas.ai/funds/brightlands-venture-partners) — Seed
- GOOSE Capital (https://capitalatlas.ai/funds/goose-capital) — Seed
- Angel Invest Ventures (https://capitalatlas.ai/funds/angel-invest-ventures) — Seed
- TechVision Fonds (https://capitalatlas.ai/funds/techvision-fonds) — Seed
- Arve Capital (https://capitalatlas.ai/funds/arve-capital) — Seed
- Leblon Capital (https://capitalatlas.ai/funds/leblon-capital) — Seed
- Inari Ventures I GmbH & Co. KG — Seed
- Wilde Ventures Gmbh — Seed